课题基金 / 基金详情

Combination strategies to improve outcome after SCI

Combination strategies to improve outcome after SCI
改善 SCI 后预后的联合策略
批准号:
6478902
负责人:
Mary Bartlett Bunge
金额:
$5.36万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-07-01 至 2002-06-30

项目摘要

项目成果

Mary Bartlett Bunge的其他基金

相似基金

相关文献

中文摘要
翻译
这些研究的最终目标是开发有效的策略,以改善人类脊髓损伤的结果。大鼠中度挫伤损伤模型,其特征在于人类中大多数损伤是通过轴突中断控制病变,如果不进行治疗,则不会发生。该提案首先描述了一系列的三个目标,比较逐步更复杂的策略,以促进再生跨越病变部位和远端脊髓。然后将在延迟的时间点测试最大化再生的策略。损伤后立即向所有大鼠注射神经保护剂。在目标1中,损伤部位将在损伤后1周通过移植在含有纤维蛋白原和成纤维细胞生长因子-I、或雪旺细胞或无鞘神经胶质(EG)、或这些再生促进细胞类型的1:1混合物的培养基中进行修饰。双标记逆行追踪技术将用于检测大脑和脑干中运动中心的神经元,这些神经元将其轴突再生到病变中。在损伤后12周,将通过计数适当标记的神经元来确定导致最高数量的轴突再生到损伤中的移植类型。在目标2中,来自目标1的最有效的移植物将在病变中脑源性神经营养因子(BDNF)和神经营养因子-3(NT-3)水平增加的情况下进行测试。将比较由1)用编码BDNF和NT-3的腺相关病毒(AAV)构建体感染的移植细胞,2)用装载BDNF/NT-3的生物可降解微球移植的未感染细胞,或3)用编码具有BDNF和NT-3活性的双功能神经营养因子的逆转录病毒构建体感染的胚胎干细胞(幼稚或星形胶质细胞限制的)诱导的轴突再生。在目标3中,这些策略中最有效的将与治疗相结合,以诱导轴突从病变中生长并进入远端脊髓。EG将仅移植到病变远端,单独或与更有效的AAV-BDNF/AAV-NT-3或BDNF/NT-3负载微球一起注射到病变远端mm处。将确定导致最多轴突再生进入远端脊髓的治疗。在所有研究中,还将使用来自皮质后肢区域、前庭外侧核和网状结构中的神经元的轴突的顺行追踪来评估再生。将使用免疫细胞化学方法对再生轴突进行分类,并确定反应轴突上trkB和trkC受体的表达。还将进行Basso-Beattie-Bresnahan旷场运动试验和电生理学分析。重要的是,在第四个也是最后一个目标中,当细胞移植和神经营养因子治疗延迟到损伤后4周和4周时,将确定切断的运动相关轴突对目标3中定义的最有效策略的反应。对损伤后轴突再生潜力随时间变化的更好理解对于预测任何再生促进策略的临床价值至关重要。
英文摘要
The ultimate goal of these studies is to develop effective strategies for improving the outcome of injuries to the spinal cord in humans. A moderate-severity contusion injury model in rats, characterize as are most injuries in humans by the interruption of axons that control lesion will not occur without treatment. This proposal first describes a series of three Aims comparing progressively more complex strategies to promote regeneration across a lesion site and into distal spinal cord. The strategy that maximizes regeneration will then be tested at delayed time points. A neuroprotective agent will be injected into all rats immediately following injury. In Aim 1, the lesion site will be modified at 1 week after injury by the transplantation, in medium containing fibrinogen and fibroblast growth factor-I, or Schwann cells or unsheathing glia (EG), or a 1:1 mixture of these regeneration-promoting cell types. A double-labeling retrograde tracing technique will be used to detect neurons in locomotion centers in the brain and brainstem which regenerate their axons into the lesion. At 12 weeks after injury the transplant type resulting in the regeneration of the highest number of axons into the lesion will be determined by counting the appropriately labeled neurons. In Aim 2, the most effective transplant from Aim 1 will be tested in the presence of increased levels of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) in the lesion. Axonal regeneration induced by 1) transplanted cells infected with adeno-associated viral (AAV) constructs coding for BDNF and NT-3, 2) uninfected cells transplanted with BDNF/NT-3 laden biodegradable microspheres, or 3) embryonic stem cells (naive or astrocyte-restricted) infected with a retroviral construct coding for a bi-functional neurotrophin with BDNF and NT-3 activity will be compared. In Aim 3, the most effective of these strategies will be combined with treatments to induce growth of the axons out of the lesion and into the distal cord. EG will be transplanted just distal to the lesion, alone or with the more effective of AAV-BDNF/AAV-NT-3 or BDNF/NT-3 laden microspheres injected mm distal to the lesion. The treatment resulting in the most axonal regeneration into the distal cord will be determined. In all studies, regeneration will also be assessed using anterograde tracing of axons from neurons in the hindlimb region of the cortex, in the lateral vestibular nucleus, and the reticular formation. Immunocytochemical methods will be used to classify the regenerating axons and to determine the expression of trkB and trkC receptors on responsive axons. Basso-Beattie-Bresnahan open field locomotion tests and electrophysiological analysis will also be performed. Importantly, in the fourth and final Aim, the response of severed locomotion-related axons to the most effective strategy defined in Aim 3 will be determined when cellular transplantation and neurotrophin treatments are delayed until 4 and 4 weeks after injury. An improved understanding of the change in potential of axons to regenerate with time after injury is critical for predicting the clinical merit of any regeneration-promoting strategy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core--Morphology
Combination strategies to improve outcome after SCI
Combination strategies to improve outcome after SCI
Core--Morphology
海外基金